摘要
目的观察文拉法辛合并氯丙嗪治疗精神分裂症阴性症状的疗效和不良反应。方法采用入院顺序分层随机法,将80例慢性精神分裂症患者分为研究组(文拉法辛+氯丙嗪)和对照组(氯丙嗪+安慰剂)。在治疗前、治疗第4,8,12周末以阳性和阴性症状量表(PANSS)总分减分率、阴性因子分减分率和不良反应量表(TESS)评定疗效和不良反应。结果治疗12周末,研究组PANSS总分减分率为(30.2±7.3)%,阴性因子分减分率为(29.3±2.1)%;对照组分别为(14.7±2.1)%,(2.8±0.7)%,差异有统计学意义(P<0.01),研究组阴性因子各项症状评分低于对照组(P<0.01)。研究组不良反应的发生率(36%)低于对照组(63%),差异均有统计学意义(P<0.01)。结论文拉法辛治疗精神分裂症安全有效,协同氯丙嗪治疗精神分裂症阴性症状可增加疗效。
Objective To observe the efficacy and side effects of venlafaxine combined with chlorpromazine in the treatment of negative symptoms in schizophrenia. Methods In this random controlled study, 80 inpatients with chronic schizophrenia were divided into two groups, with one treated with venlafaxine combined chlorpromazine and the other with chlorpromazine combined placebo. Effects and side effects were assessed with the Positive and Negative Syndrome Scale （PANSS） and Treatment Emergent Symptoms Scale （TESS） respectively before and after 4, 8, 12 week treatment. Results The reduction on PANSS score and on negative symptom scale at weeks 12 were （ 30.2 ± 7.3 ） % and （ 29.3 ± 2.1 ） % in venlafaxine combined group, which were higher than that in placebo combined group[ （14.7± 2.1 ）% and （2.8 ±0.7）%, P 〈 0.01 ]. The TESS scores at weeks 4, 8, 12 in venlafaxine group were lower than that in placebo group. Conclusion It is suggested venlafaxine in combination with typical antipsychotics is effective and safe in treatment of the negative symptom in schizophrenia patients.
出处
《中华精神科杂志》
CAS
CSCD
北大核心
2006年第2期90-93,共4页
Chinese Journal of Psychiatry
关键词
精神分裂症
氯丙嗪
阴性症状
文拉法辛
Schizophrenia
Chlorpromazine
Negative symptom
Venlafaxine
